159 related articles for article (PubMed ID: 22964958)
41. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665
[TBL] [Abstract][Full Text] [Related]
42. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
43. Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients: a randomized double-blind placebo-controlled trial.
de Quadros Onófrio F; Lima JCP; Watte G; Lehmen RL; Oba D; Camargo G; Dos Santos CEO
Surg Endosc; 2017 May; 31(5):2317-2324. PubMed ID: 27651353
[TBL] [Abstract][Full Text] [Related]
44. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
Hesketh PJ; Grunberg SM; Gralla RJ; Warr DG; Roila F; de Wit R; Chawla SP; Carides AD; Ianus J; Elmer ME; Evans JK; Beck K; Reines S; Horgan KJ;
J Clin Oncol; 2003 Nov; 21(22):4112-9. PubMed ID: 14559886
[TBL] [Abstract][Full Text] [Related]
45. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
Kaffes AJ; Bourke MJ; Ding S; Alrubaie A; Kwan V; Williams SJ
Gastrointest Endosc; 2006 Sep; 64(3):351-7. PubMed ID: 16923481
[TBL] [Abstract][Full Text] [Related]
46. Lactated Ringer's solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission: a prospective randomized, double-blinded, placebo-controlled trial.
Mok SRS; Ho HC; Shah P; Patel M; Gaughan JP; Elfant AB
Gastrointest Endosc; 2017 May; 85(5):1005-1013. PubMed ID: 27816497
[TBL] [Abstract][Full Text] [Related]
47. Vigorous Periprocedural Hydration With Lactated Ringer's Solution Reduces the Risk of Pancreatitis After Retrograde Cholangiopancreatography in Hospitalized Patients.
Choi JH; Kim HJ; Lee BU; Kim TH; Song IH
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):86-92.e1. PubMed ID: 27311618
[TBL] [Abstract][Full Text] [Related]
48. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Bai Y; Xu C; Yang X; Gao J; Zou DW; Li ZS
Endoscopy; 2009 Aug; 41(8):690-5. PubMed ID: 19670137
[TBL] [Abstract][Full Text] [Related]
49. Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial.
Oh HC; Cheon YK; Cho YD; Do JH
Gastrointest Endosc; 2011 Sep; 74(3):556-62. PubMed ID: 21802079
[TBL] [Abstract][Full Text] [Related]
50. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
Choi CW; Kang DH; Kim GH; Eum JS; Lee SM; Song GA; Kim DU; Kim ID; Cho M
Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
[TBL] [Abstract][Full Text] [Related]
51. The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
Tsujino T; Isayama H; Nakai Y; Ito Y; Togawa O; Toda N; Arizumi T; Kogure H; Yamamoto K; Mizuno S; Yashima Y; Yagioka H; Sasaki T; Matsubara S; Yamamoto N; Hirano K; Sasahira N; Tada M; Koike K
J Gastroenterol; 2013 Aug; 48(8):982-8. PubMed ID: 23090004
[TBL] [Abstract][Full Text] [Related]
52. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial.
Dumot JA; Conwell DL; O'Connor JB; Ferguson DR; Vargo JJ; Barnes DS; Shay SS; Sterling MJ; Horth KS; Issa K; Ponsky JL; Zuccaro G
Am J Gastroenterol; 1998 Jan; 93(1):61-5. PubMed ID: 9448176
[TBL] [Abstract][Full Text] [Related]
53. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial.
Barkay O; Niv E; Santo E; Bruck R; Hallak A; Konikoff FM
Surg Endosc; 2008 Sep; 22(9):1971-6. PubMed ID: 18214607
[TBL] [Abstract][Full Text] [Related]
54. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.
Hu Z; Cheng Y; Zhang H; Zhou C; Han B; Zhang Y; Huang C; Chang J; Song X; Liang J; Liang H; Bai C; Yu S; Chen J; Wang J; Pan H; Chitkara DK; Hille DA; Zhang L
Support Care Cancer; 2014 Apr; 22(4):979-87. PubMed ID: 24276953
[TBL] [Abstract][Full Text] [Related]
55. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Xiong GS; Wu SM; Zhang XW; Ge ZZ
Braz J Med Biol Res; 2006 Jan; 39(1):85-90. PubMed ID: 16400468
[TBL] [Abstract][Full Text] [Related]
56. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
[TBL] [Abstract][Full Text] [Related]
57. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis.
Mosler P; Sherman S; Marks J; Watkins JL; Geenen JE; Jamidar P; Fogel EL; Lazzell-Pannell L; Temkit M; Tarnasky P; Block KP; Frakes JT; Aziz AA; Malik P; Nickl N; Slivka A; Goff J; Lehman GA
Gastrointest Endosc; 2005 Aug; 62(2):245-50. PubMed ID: 16046988
[TBL] [Abstract][Full Text] [Related]
58. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study.
De Palma GD; Catanzano C
Am J Gastroenterol; 1999 Apr; 94(4):982-5. PubMed ID: 10201469
[TBL] [Abstract][Full Text] [Related]
59. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study.
Sherman S; Blaut U; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Earle D; Temkit M; Lehman GA
Gastrointest Endosc; 2003 Jul; 58(1):23-9. PubMed ID: 12838216
[TBL] [Abstract][Full Text] [Related]
60. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study.
Kwanngern K; Tiyapattanaputi P; Wanitpukdeedecha M; Navicharern P
J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S42-5. PubMed ID: 16623000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
